PFS as an Endpoint in Ovarian Cancer Clinical Trials

January 5, 2015
Jason D. Wright, MD

Jason D. Wright, MD, discusses progression-free survival (PFS) as an endpoint for ovarian cancer trials.

Clinical Pearls

Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses progression-free survival (PFS) as an endpoint for ovarian cancer trials.

  • PFS is the most commonly used endpoint for ovarian cancer clinical trials.
  • PFS is relatively easily measured and can be measured in a timely fashion.
  • However, PFS does not always correlate with overall survival.

Olaparib was recently approved for ovarian cancer.Read more > >